TolerRx's TRX4 meets Phase II endpoint

TolerRx (Cambridge, Mass.) said TRX4 ( ChAglyCD3) met the primary endpoint of difference in beta cell function from baseline in a Phase II trial to treat Type I diabetes (p<0.02). In the double-blind,...